Capecitabine and Gemcitabine with Radiation for Pancreatic Cancer
Author Information
Author(s): Michael M, Price T, Ngan S Y, Ganju V, Strickland A H, Muller A, Khamly K, Milner A D, Dilulio J, Matera A, Zalcberg J R, Leong T
Primary Institution: Peter MacCallum Cancer Centre
Hypothesis
The aim of this phase I trial was to determine the highest administered dose of the Cap plus Gem combination with radical radiotherapy for locally advanced pancreatic cancer.
Conclusion
The addition of Capecitabine and Gemcitabine to radical radiation therapy was feasible and effective for patients with locally advanced pancreatic cancer.
Supporting Evidence
- The disease control rate was 75%, with a median overall survival of 11.2 months.
- Two patients experienced dose-limiting toxicities, indicating the treatment's safety profile.
- Patients were carefully selected based on specific inclusion criteria to ensure safety.
Takeaway
This study tested a new combination of medicines to help people with a tough kind of pancreatic cancer, and it worked pretty well.
Methodology
Patients with locally advanced pancreatic cancer received a combination of Capecitabine and Gemcitabine along with radiation therapy, with doses adjusted based on tolerance.
Limitations
The small sample size and the phase I nature of the trial limit the generalizability of the results.
Participant Demographics
{"gender_distribution":{"male":12,"female":8},"age_range":"41-80","median_age":64}
Statistical Information
Confidence Interval
9.4–14.4 months
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website